Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    Dr Eddy Stevens, Chief Scientific Officer, Metrion Biosciences
    28 April 2025

    Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain

    Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signallingCompletes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation programmesCambridge, UK, 28 ...

    www.tecan.com
    28 April 2025

    BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

    Combines BioSkyrb’s new ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit 384-well assay with Uno Single Cell Dispenser™ provided by Tecan in a single workflowEnables scalable, high-throughput analysis of hundreds to thousands of single cells, advancing applications in can...

    BioResource Science Conference 2025 Graphic
    24 April 2025

    Speakers announced for the BioResource Scientific Conference 2025

    We are excited to present our speakers for the 3rd annual NIHR BioResource Scientific Conference, taking place online on Wednesday 25 June 2025 from 9.30am to 12.30pm.  ...

    Ben Standing raising money for Addenbrooke's Charitable Trust
    24 April 2025

    Patient with rare inflammatory disease of the nervous system turns to music to raise funds for Addenbrooke's

    Fundraiser Ben Standing first noticed something was wrong when he started veering across pavements whilst on holiday and after an inconclusive scan halted his imminent chemo treatment, he discovered he had a rare condition called CLIPPERS... ...

    Dr Tomasz Kostrzewski, CSO, CN Bio	and Dr Hua Yang, CSO, Pharmaron
    24 April 2025

    CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform

    Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development ...

    Dr. Edward Hodgkin, Managing Partner, Syncona Investment Management Limited and Chair, Mosaic Therapeutics	 and Dr. Harren Jhoti, Co-founder, President and CEO, Astex Pharmaceuticals and	Magdalena Jonikas, CEO, Mosaic Therapeutics
    24 April 2025

    Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

    In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets As part of the agreement A...

    Pipeline Publishing
    30 April 2025

    Outpacing change in cellular connectivity

    By Bruce Lancaster

    Divik Seth jpg.
    23 April 2025

    Divik Seth joins Salus Wellness

    We are very pleased to announce that Divik Seth has joined Salus Wellness this month. ...

    Biodesix logo
    23 April 2025

    Biodesix partner - Friends of Cancer Research, publishes study linking ctDNA changes to solid tumour treatment outcomes

    Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology ...

    Pierre Arsène, Founder and CEO, Mursla Bio
    23 April 2025

    Mursla Bio receives FDA breakthrough device designation for EvoLiver Test

    Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles circulating in blood Breakthrough status provides expedited review and closer collab...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 97
    • Page 98
    • Current page 99
    • Page 100
    • Page 101
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS